Search Results

Accuray Incorporated announced that long-term customer Heidelberg University Hospital in Heidelberg, Germany, has selected the company’s Radixact® System, equipped with its proprietary ClearRT®, Synchrony® and VOLO™ Ultra Optimizer solutions, to help transform their approach to cancer care.

Fusion Pharmaceuticals Inc. announced that it has entered into an exclusive worldwide license agreement with Heidelberg University and Euratom represented by the European Commission, Joint Research Centre.

BioMed X, a German biomedical research institute, announces the start of a new research project in partnership with Merck at its site in Heidelberg, Germany.

AGC Biologics today announced the completion of the facility expansion for its new plasmid DNA (pDNA) and messenger RNA (mRNA) production line at the CDMO’s Heidelberg, Germany site.

The diagnostic company SphingoTec GmbH announces the introduction of novel biomarker penKid in the clinical routine management of patients on a test basis in a total of four units at the University Hospital Heidelberg and Heidelberg Kidney Center.

Heidelberg Engineering, a global leader in ophthalmic imaging and healthcare data solutions, announces FDA clearance of its innovative all-in-one ANTERION® platform, designed to transform anterior segment diagnostics and streamline practice workflow.

Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma ™ Fully Digital Surgical Visualization Platform.

An international gathering of biological engineers, cell biologists, and affiliated scientists will discuss breakthroughs in optogenetics research, and how these technologies are translating to real-world applications, including healthcare, industry, and other areas, at the 3rd Optogenetic Technologies and Applications Conference, to be held December 1–3, 2022, at the Heidelberg Marriott Hotel in Heidelberg, Germany.

The new research team at the BioMed X Institute in Heidelberg will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.